Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.69 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 8/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507011 | 1.00 | GPR84 (0.69) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL31040068 | 0.92 | GPR84 (0.69) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL1565699 | 0.92 | GPR84 (0.69) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL23932310 | 0.82 | CSNK2A1 (0.69) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL188052 | 0.82 | GPR84 (1.00) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL28512403 | 0.76 | TRPA1 (0.56) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL7137304 | 0.76 | GPR84 (0.58) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL917519 | 0.75 | CSNK2A1 (0.55) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL1076943 | 0.75 | CSNK2A1 (0.85) | GPR84CSNK2A1AHRCYP2A6NR4A2 | |
| SCHEMBL30573025 | 0.75 | CSNK2A1 (0.55) | GPR84CSNK2A1AHRCYP2A6NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805664-B | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115784966-A | Preparation method of 6-bromo-5-fluoroindole-2-ketone | 上海泰坦科技股份有限公司 | 2023-03-14 | — | — | CN | claimed |
| CN-114805664-A | Bionic modified marine antifouling resin material, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| CN-114292582-B | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-114292582-A | Hyperbranched coating suitable for marine concrete, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-4741383-A1 | COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12577232-B2 | N-heterocycle substituted tryptamine derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2026-03-17 | — | — | US | disclosed |
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
| US-20250353830-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4648762-A2 | PPARG MODULATORS | University of Florida Research Foundation, Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| US-20250289805-A1 | N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-09-18 | — | — | US | disclosed |
| US-12358878-B2 | N-aromatic amide compounds, preparation methods and uses thereof | SHENZHEN EDK PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| EP-1660484-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-6979696-B2 | Method for detecting a gram-negative bacterial autoinducer molecule | ROCHE PALO ALTO LLC (US) | 2005-12-27 | — | — | US | disclosed |
| WO-2005102998-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2005-11-03 | — | — | WO | disclosed |
| WO-2004099189-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPH-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ROCHE PALO ALTO LLC | 2004-11-11 | — | — | US | disclosed |
| US-6380238-B1 | FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-30 | — | — | US | disclosed |
| EP-1109784-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012475-A1 | INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ADRA1A, ADRB1, ADRA1D | GPR84 96/4885CSNK2A1 1009/4885AHR 210/4885 |
| US-20250353830-A1 | NOVEL COMPOUNDS | UQCRB, CCNB3, C5 | GPR84 2429/4885CSNK2A1 2005/4885AHR 1827/4885 |
| US-20250289805-A1 | N-HETEROCYCLE SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR2C, HTR2A, HTR5A | GPR84 265/4885CSNK2A1 2418/4885AHR 178/4885 |
| US-12577232-B2 | N-heterocycle substituted tryptamine derivatives and methods of using | HTR2C, TPH2, HTR4 | GPR84 680/4885CSNK2A1 1056/4885AHR 136/4885 |
| US-12358878-B2 | N-aromatic amide compounds, preparation methods and uses thereof | H1-3, H1-0, NAT1 | GPR84 2452/4885CSNK2A1 2779/4885AHR 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.